A population‐based study of renal cell carcinoma and prostate cancer in the same patients

Abstract

OBJECTIVETo investigate the incidence of prostate cancer in men with renal cell carcinoma (RCC) and the incidence of RCC in men with prostate cancer. METHODSWe evaluated the database of the Surveillance, Epidemiology and End Results Program of the National Cancer Institute from 1973 to 1996, to calculate the incidence of RCC in men with prostate cancer and the incidence of prostate cancer in men with RCC. The standardized incidence ratio (SIR, observed/expected) was calculated for each of the scenarios of interest, as well as for RCC and prostate cancer in men with other common malignancies. Lung/bronchus cancer, colon/rectal cancer, and non-Hodgkin lymphoma were selected for the control scenarios because they are the most common non-urological cancers among men in the USA. RESULTSThere was a higher incidence of RCC in men with prostate cancer (SIR 1.25, P < 0.01). RCC incidence was also higher in men with each of the other malignancies. Prostate cancer incidence was higher in men with RCC (SIR 1.42, P < 0.001), but was not significantly elevated for any of the control scenarios. CONCLUSIONSThe incidence of RCC is higher in men with each of the index cancers, whereas that for prostate cancer was higher only in men with RCC. A common aetiological factor is possible. However, it is also possible that detection bias explains these findings. Serial imaging might increase the detection of RCC among patients with a variety of index malignancies. Patients with RCC who are followed by a urologist might be screened more rigorously for prostate cancer than patients with other primary malignancies, leading to increased detection in these men.

Proteome dynamics analysis identifies functional roles of SDE2 and hypoxia in DNA damage response in prostate cancer cells

“…Interestingly, our data showed that pathways related to renal cell carcinoma (RCC) were significantly upregulated upon hypoxia treatment of prostate cancer cells. Previous clinical studies have shown that men with prostate cancer have a significantly higher chance of developing RCC ( 37 ). Accordingly, our analysis showed that hypoxia microenvironment in prostate cancer cells significantly upregulated MET and ETS1 to activate key cell proliferation signaling cascades that are important for RCC while upregulating GLUT1 and VEGF to increase nutrient availability, potentially promoting the subsequent development of RCC in prostate cancer patients ( 38 ).…”

Understanding the way we think

“…The finding that increased detection of prostate cancer did not translate into improved cancer‐specific outcomes may be considered worrisome and potentially reinforce policymakers against screening for prostate cancer. As such, whilst these findings have been reported before , these questions have never been as significant as they are now, in the ‘Obamacare’ era.…”

The risk of development of multiple primary malignant tumors involving the thyroid gland

“…Таким образом, в нашем исследовании установлено, что у больных полинеоплазиями с поражением щитовидной железы более высокий, чем в популяции, RR развития других злокачественных новообразований. Так, у женщин, больных раком щитовидной железы, высокий RR синхронного и метахронного развития меланомы (20,6 и 17,1 соответственно), злокачественных новообразований почки (46,3 и 18,5), шейки матки (13,1 и 15,8), молочной железы (11,0 и 11,5) и кожи (8,5 и 9,5 соответственно), метахронного развития лимфом (31,7), рака лёгких и бронхов (18,8), ободочной кишки (16,7), тела матки (11,8), а также синхронного развития рака пищевода (17,8). У мужчин высокий RR синхронного и метахронного развития лимфом (12,8 и 41,8 соответственно), рака почки (33,8 и 55,6) и предстательной железы (24,4 и 35,7), синхронного развития рака пищевода (19,4) и прямой кишки (19,0).…”

“…Так же, как и в настоящей работе, независимые группы учёных не выявили увеличения риска развития карцином щитовидной железы у больных раком предстательной железы [8,14].…”

“…По данным других авторов, как и по нашим данным, у больных с первично-множественными злокачественными опухолями с поражением ободочной и прямой кишки риск развития рака щитовидной железы был достоверно высоким [6]. Также в ряде исследований авторы, как и мы, не выявили у больных раком почки повышенного риска развития карциномы щитовидной железы [8].…”